Title
Category
Credits
Event date
Cost
Therapeutic Advances for Epileptic Seizure Rescue
  • Epilepsy
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Neurologists and other clinicians can improve care by identifying individuals who are susceptible to seizure clusters and educating them on rescue therapies and medications.
Diagnosing and Treating Alzheimer Disease During the Early Stage
  • Alzheimer Disease
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Many new therapies for early-stage AD have made their way onto the scene that can delay onset of the disease and/or slow down progression. Find out the how, what, when to better treat your patients with AD from specialists in the field.
Comparing LAI and Oral Antipsychotic Options: Expert Discussions with Schizophrenia Case Reports
  • Schizophrenia/ Schizoaffective Disorders
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
LAI antipsychotics are often initiated late in adults with schizophrenia, despite evidence supporting early use. Experts discuss the barriers to initiating LAI treatment, as well as adherence, efficacy and safety data.
Tweetorial: Parkinson’s Disease Psychosis: Best Practices for Diagnosing PDP
  • Parkinson Disease
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
Parkinson’s disease psychosis (PDP) is a nonmotor symptom of Parkinson’s disease (PD) and includes at least 1 symptom of hallucinations, illusions, delusions, or false sense of presence after onset of PD and recurrent/continuous for 1 month or more.
Tweetorial: Parkinson’s Disease Psychosis: Current Therapies for Patients with PDP
  • Parkinson Disease
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
Management for Parkinson's disease psychosis (PDP) includes evaluating triggers, non-Parkinson's drugs, Parkinson's drugs that may contribute to symptoms, behavioral interventions, and multidisciplinary collaboration between health providers.
Agitation in Bipolar Disorder and Schizophrenia: Emergency Department Considerations
  • Bipolar Disorder
  • Schizophrenia/ Schizoaffective Disorders
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
In treating agitation in bipolar disorder/schizophrenia in the emergency department, consider efficacy and safety of therapies as well as the safety of patient and staff.
Cognitive Impairment in Huntington Disease
  • Movement Disorders
  • Neurology
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
An updated review of pathophysiology, emerging treatments, and supportive care strategies in the cognitive dimension of Huntington disease.
Tweetorial: Reviewing LAI vs. Oral Data in the Treatment of Schizophrenia
  • Schizophrenia/ Schizoaffective Disorders
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
Experts compare data on hospitalization, adherence, relapse risk, tolerance and efficacy between LAIs and OAs in the treatment of schizophrenia.
Tweetorial: Analyzing Two Schizophrenia Case Reports
  • Schizophrenia/ Schizoaffective Disorders
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
Experts discuss appropriate treatment sequencing for patients with schizophrenia, including early use of LAIs and switching from an oral antipsychotic.
A Tailored Approach to Diagnosis and Early Treatment in Patients with Duchenne Muscular Dystrophy: A Real-World View of Quality of Life
  • Delivery of Care
  • Muscular Dystrophy
  • Neurology
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
A detailed, modern digest of key advances in the diagnosis, treatment, and management of patients with Duchenne muscular dystrophy.

Pages